<DOC>
	<DOCNO>NCT01814423</DOCNO>
	<brief_summary>Chloroquine ( CQ ) remain alternative cheap , safe widely available drug . Our previous research show double ( 50 mg/kg ) standard dose CQ give split dose 95 % efficacy well tolerate safe . Still , safety could issue dose CQ increase . Severe adverse event cause high peak concentration CQ . Using split dos CQ avoids high peak concentration enable safe administration high dos , however , pharmacokinetic data lacking . Children include study give 50 mg/kg split dose 3 day 70 mg/kg split dose 5 day . Treatment observe . Drug concentration adverse event monitor . On day 1 , child mother/guardian request stay health centre 9 6 pm . Fifteen child age 2-10 year uncomplicated P. falciparum malaria fulfil inclusion criterion recruit study arm . Following end treatment , child see morning day 7 , 14 , 21 28 . Any child wish withdraw treatment phase child reparasitaemia follow give rescue treatment arthemeter-lumefantrine quinine accord treatment guideline Guinea-Bissau . Final analysis include description include child , proportion adverse event serious adverse event , drug concentration relation adverse event , proportion child withdraw lose follow , cumulative PCR correct uncorrected success failure rate day 28 proportion early , late clinical late parasitological treatment failure .</brief_summary>
	<brief_title>Pharmacokinetic Study Multi-dose Chloroquine</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Age ≥ 2 year &lt; 10 year . Monoinfection P. falciparum detect microscopy . Parasitemia 1.000100.000/µl asexual form . Axillary temperature ≥ 37.5 ˚C history fever within 24 hour . Ability swallow oral medication . Ability willingness comply study protocol . Informed consent parent guardian Signs symptom severe malaria . Presence general danger sign child 5 . Persistent vomit . Presence severe malnutrition . Any evidence chronic disease acute infection malaria . Regular medication may interfere antimalarial pharmacokinetics . History hypersensitivity reaction contraindication chloroquine .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>malaria</keyword>
	<keyword>chloroquine</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>child</keyword>
</DOC>